Homcy Charles J's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Aug 12, 2025
- Accession no.
- 0000950170-25-107510
- Filed
- Aug 12, 2025
- Trade date
- Aug 8-11, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $13.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Homcy Charles JCIK 0001192591 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | Common Stock | SSaleDisposed | −191,662 | $45.87 | −$8,791,535.94 | 1,025,012 | Direct | |
| Aug 8, 2025 | Common Stock | SSaleDisposed | −58,338 | $46.64 | −$2,720,884.32 | 966,674 | Direct | |
| Aug 11, 2025 | Common Stock | SSaleDisposed | −50,000 | $48.00 | −$2,400,000 | 916,674 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.